Are Goyal Associates Ltd latest results good or bad?

1 hour ago
share
Share Via
Goyal Associates Ltd's latest results are concerning, showing a net loss of ₹0.39 crores and a 22.45% decline in revenue year-on-year, alongside a drastic drop in operating margins and return on equity. Overall, the company is facing significant operational challenges that warrant close monitoring by investors.
The latest financial results for Goyal Associates Ltd for the quarter ended March 2026 present a challenging scenario for the company. The net profit for this quarter was reported as a loss of ₹0.39 crores, a significant decline from a profit of ₹0.13 crores in the same quarter the previous year. This marks a stark shift in profitability, indicating operational difficulties.
Revenue for the quarter was ₹0.38 crores, which reflects a year-on-year decline of 22.45% from ₹0.49 crores. However, there was a sequential improvement of 31.03% from the previous quarter's revenue of ₹0.29 crores. Despite this sequential growth, the overall revenue figures suggest that the company's core lending activities are under considerable pressure. The operating margin also saw a notable decline, with the company reporting an operating loss of ₹0.45 crores, resulting in an operating margin of -118.42%. This is a drastic drop from a positive margin of 38.78% in the same quarter last year, indicating that the company's operational efficiency has been severely impacted. Return on equity (ROE) has also declined sharply, averaging 11.65% over the measurement period but dropping to just 4.31% in the latest quarter. This deterioration reflects the challenges the company is facing in generating returns on its equity base. Overall, Goyal Associates Ltd's financial results highlight significant operational struggles, with a marked decline in profitability and revenue, alongside a concerning collapse in operating margins. The company saw an adjustment in its evaluation, reflecting these underlying challenges. Investors may need to closely monitor future performance to assess any potential recovery or further deterioration in the company's financial health.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News